Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer.

Abstract:

OBJECTIVE:The national guidelines recommend more intensive screening for breast cancer for women with a family history of breast or ovarian cancer. Using the data from the 2000 National Health Interview Survey (NHIS), we examined factors related to the underuse of mammogram in this population. METHOD:The study subjects were 1,215 women aged 30-79 who had a family history of breast or ovarian cancer in their first-degree relatives. According to the American Cancer Society's guidelines for breast cancer screening, having no mammogram in last year was used as an outcome for this study. Socio-demographic characteristics, health-related conditions, lifestyle factors, health behaviors, menstrual/reproductive information and health care access and utilization were analyzed to assess their relations to mammogram underuse using unconditional logistic regression method. RESULTS:The results showed that younger age, having no place to go when sick (OR = 2.2, 95% CI, 1.2-4.0), having no visits to a general doctor (OR = 1.7, 95% CI, 1.2-2.4) or medical specialist (OR = 2.2, 95% CI, 1.6-3.1) and having no influenza shot in last year (OR = 1.7, 95% CI, 1.2-2.3) increased the risk of underusing mammography screening among women who had a family history of breast or ovarian cancer. Women who had no home care from health professionals in the last year were less likely to underuse mammogram with an OR of 0.3 (95% CI, 0.1-0.6), compared with women who had. CONCLUSION:Medical care-related factors may affect the use of mammography screening in women with a family history of breast or ovarian cancer.

authors

Wu H,Zhu K,Jatoi I,Shah M,Shriver CD,Potter J

doi

10.1007/s10549-006-9298-5

subject

Has Abstract

pub_date

2007-03-01 00:00:00

pages

317-24

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

101

pub_type

杂志文章
  • Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: a reappraisal.

    abstract::A review of the current literature on immunohistologic and histochemical methods for the detection of steroid hormone binding sites in breast cancer, reveals that many, but not all of the criteria for establishing hormone-receptor binding interactions have been met. These include tissue specificity, binding between la...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806746

    authors: Pertschuk LP,Tobin EH,Carter AC,Eisenberg KB,Leo VC,Gaetjens E,Bloom ND

    更新日期:1981-01-01 00:00:00

  • Syndecan-1 facilitates breast cancer metastasis to the brain.

    abstract:PURPOSE:Although survival rates for patients with localized breast cancer have increased, patients with metastatic breast cancer still have poor prognosis. Understanding key factors involved in promoting breast cancer metastasis is imperative for better treatments. In this study, we investigated the role of syndecan-1 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05347-0

    authors: Sayyad MR,Puchalapalli M,Vergara NG,Wangensteen SM,Moore M,Mu L,Edwards C,Anderson A,Kall S,Sullivan M,Dozmorov M,Singh J,Idowu MO,Koblinski JE

    更新日期:2019-11-01 00:00:00

  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

    abstract::FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2556-4

    authors: Lal A,Chan L,Devries S,Chin K,Scott GK,Benz CC,Chen YY,Waldman FM,Hwang ES

    更新日期:2013-06-01 00:00:00

  • Predictors of time to death after distant recurrence in breast cancer patients.

    abstract:BACKGROUND:After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients wi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5002-9

    authors: Sopik V,Sun P,Narod SA

    更新日期:2019-01-01 00:00:00

  • Analyzing factors associated with women's attitudes and behaviors toward screening mammography using design-based logistic regression.

    abstract::We examined the factors associated with screening mammography adherence behaviors and influencing factors on women's attitudes toward mammography in non-adherent women. Design-based logistic regression models were developed to characterize the influencing factors, including socio-demographic, health related, behaviora...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2850-9

    authors: Madadi M,Zhang S,Yeary KH,Henderson LM

    更新日期:2014-02-01 00:00:00

  • Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.

    abstract:PURPOSE:The methods (IHC/FISH) typically used to assess ER, PR, HER2, and Ki67 in FFPE specimens from breast cancer patients are difficult to set up, perform, and standardize for use in low and middle-income countries. Use of an automated diagnostic platform (GeneXpert®) and assay (Xpert® Breast Cancer STRAT4) that emp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4889-5

    authors: Wu NC,Wong W,Ho KE,Chu VC,Rizo A,Davenport S,Kelly D,Makar R,Jassem J,Duchnowska R,Biernat W,Radecka B,Fujita T,Klein JL,Stonecypher M,Ohta S,Juhl H,Weidler JM,Bates M,Press MF

    更新日期:2018-11-01 00:00:00

  • Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

    abstract::The effect of 17-beta-estradiol (E2) on the induction of osteolytic lesions by estrogen receptor (ER)-negative breast cancer cells was investigated in 4-week-old female nude mice. Exposure to exogenous E2 was found to increase osteolytic areas on radiographs up to 5.3 times in mice inoculated intracardially with MDA-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1022943127689

    authors: Winding B,Misander H,Høegh-Andersen P,Brünner N,Foged NT

    更新日期:2003-03-01 00:00:00

  • Rho proteins and cancer.

    abstract::The Rho family of GTPases has been intensively studied for their roles in signal transduction processes leading to cytoskeletal-dependent responses, including cell migration and phagocytosis. In addition, they are important regulators of cell cycle progression and affect the expression of a number of genes, including ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/B:BREA.0000018423.47497.c6

    authors: Ridley AJ

    更新日期:2004-03-01 00:00:00

  • Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.

    abstract:PURPOSE:To evaluate the effect of adjuvant chemotherapy on improving the prognosis of patients with stage I triple-negative breast cancer (TNBC). METHODS:TNBC patients diagnosed in the SEER 18 database from 2010 to 2015 were included. Kaplan-Meier plots and log-rank tests were used to compare the differences in breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05776-2

    authors: Du ZL,Wang Y,Wang DY,Zhang L,Bian ZM,Deng Y,Xu CS,Lin DC,Xie L,Jia Y,Gao JD,Zhang BL

    更新日期:2020-09-01 00:00:00

  • Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer.

    abstract::Mastopathy is a common disease of the breast likely associated with elevated estrogen levels and a putative risk factor for breast cancer. The role of estrogen receptor alpha (ESR1) in mastopathy has not been investigated previously. Here, we investigated the prevalence of ESR1 gene amplification in mastopathy and its...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3427-y

    authors: Soysal SD,Kilic IB,Regenbrecht CR,Schneider S,Muenst S,Kilic N,Güth U,Dietel M,Terracciano LM,Kilic E

    更新日期:2015-06-01 00:00:00

  • Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study.

    abstract:PURPOSE:To assess the association between benign ovarian tumors and subsequent risk of breast cancer, and to examine this association according to type of benign ovarian tumors. METHODS:This nationwide cohort study comprised all Danish women diagnosed with a benign ovarian tumor during 1978-2016 (n = 158,221) identifi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05369-8

    authors: Gottschau M,Jensen A,Reinholdt K,Guleria S,Munk C,Mellemkjær L,Kjær SK

    更新日期:2019-11-01 00:00:00

  • Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

    abstract:PURPOSE:To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before high dose chemotherapy and to study the pharmacokinetic interactions of these three drugs. PATIENTS AND METHOD...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1011945623464

    authors: Conte PF,Gennari A,Donati S,Salvadori B,Baldini E,Bengala C,Pazzagli I,Orlandini C,Danesi R,Fogli S,Del Tacca M

    更新日期:2001-07-01 00:00:00

  • Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

    abstract::NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to determine if trastuzu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2755-z

    authors: Siziopikou KP,Anderson SJ,Cobleigh MA,Julian TB,Arthur DW,Zheng P,Mamounas EP,Pajon ER,Behrens RJ,Eakle JF,Leasure NC,Atkins JN,Polikoff JA,Seay TE,McCaskill-Stevens WJ,Rabinovitch R,Costantino JP,Wolmark N

    更新日期:2013-11-01 00:00:00

  • Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.

    abstract:PURPOSE:To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS:A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-u...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4491-2

    authors: Siegelmann-Danieli N,Katzir I,Landes JV,Segal Y,Bachar R,Rabinovich HR,Bialik M,Azuri J,Porath A,Lomnicky Y

    更新日期:2018-01-01 00:00:00

  • Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction.

    abstract::A new method of measuring gene copy number in small samples of DNA was used to measure amplification of the erbB-2 gene and of chromosome 20q in breast cancer. This method, termed 'differentially competitive polymerase chain reaction' (DC-PCR) combines the advantages of two other techniques for measuring amplification...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806816

    authors: Deng G,Yu M,Chen LC,Moore D,Kurisu W,Kallioniemi A,Waldman FM,Collins C,Smith HS

    更新日期:1996-01-01 00:00:00

  • Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype.

    abstract:PURPOSE:The significance of HER-2/neu results obtained by immunohistochemical analyses (IHC) which are neither negative nor strongly positive is controversial. The incidence of fluorescence in situ hybridization (FISH) positivity in these tumors is small and the implication is that these borderline results represent la...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9136-1

    authors: Killeen JL,Ortega-Lopez A,Shaha J,Shaha SH,Fu JB

    更新日期:2006-07-01 00:00:00

  • Transforming growth factor-beta in breast cancer: a working hypothesis.

    abstract::Transforming Growth Factor-beta (TGF beta) is the most potent known inhibitor of the progression of normal mammary epithelial cells through the cell cycle. During the early stages of breast cancer development, the transformed epithelial cells appear to still be sensitive to TGF beta-mediated growth arrest, and TGF bet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005865812918

    authors: Reiss M,Barcellos-Hoff MH

    更新日期:1997-08-01 00:00:00

  • Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation.

    abstract::Inositol hexaphosphate (IP6) is a naturally occurring polyphosphorylated carbohydrate with demonstrated anti-proliferative and anti-cancer activity in mammary cells. We hypothesized that IP6 modulates cell cycle proteins by action on cytoplasmic signaling molecules. The effects of both pharmacological (2 mM) and physi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-6456-5

    authors: Vucenik I,Ramakrishna G,Tantivejkul K,Anderson LM,Ramljak D

    更新日期:2005-05-01 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract::Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-013-2611-1

    authors: Russo AL,Taghian AG

    更新日期:2013-07-01 00:00:00

  • Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

    abstract:PURPOSE:To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-008-0055-9

    authors: Dickler MN,Cobleigh MA,Miller KD,Klein PM,Winer EP

    更新日期:2009-05-01 00:00:00

  • Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.

    abstract::We determined the expression of two transcriptional variants of thyroid hormone receptor alpha (THRα1 and THRα2) in samples from a cohort of breast cancer patients and correlated expression levels with survival. 130 women who were diagnosed with invasive breast carcinoma between 2007 and 2008 were included. Representa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3235-9

    authors: Jerzak KJ,Cockburn J,Pond GR,Pritchard KI,Narod SA,Dhesy-Thind SK,Bane A

    更新日期:2015-01-01 00:00:00

  • Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).

    abstract::Bone lesions as a consequence of bone metastases in breast cancer patients can increase risk for skeletal-related events (SREs) (i.e., radiation to the bone, a pathological or osteoporotic fracture event, hypercalcemia, spinal cord compression, or surgery to the bone). The mortality risk for breast cancer patients wit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1475-5

    authors: Yong M,Jensen AÖ,Jacobsen JB,Nørgaard M,Fryzek JP,Sørensen HT

    更新日期:2011-09-01 00:00:00

  • Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin.

    abstract::Serum melatonin (MLT) levels have been reported to diminish significantly by the 5th and 6th decades of life as the incidence of breast cancer increases. Given MLT's anti-cancer activity, we hypothesize that age-related decline in pineal MLT production leads to enhanced breast cancer development and growth as women ag...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0958-0

    authors: Hill SM,Cheng C,Yuan L,Mao L,Jockers R,Dauchy B,Frasch T,Blask DE

    更新日期:2011-05-01 00:00:00

  • The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

    abstract::The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it wi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3308-4

    authors: Jerjees DA,Negm OH,Alabdullah ML,Mirza S,Alkaabi M,Hameed MR,Abduljabbar R,Muftah A,Nolan CC,Green AR,Tighe PJ,Band V,Ellis IO,Rakha EA

    更新日期:2015-02-01 00:00:00

  • Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

    abstract::Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665803

    authors: Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

    更新日期:1993-01-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract:INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-013-2639-2

    authors: Ahmed M,Douek M

    更新日期:2013-08-01 00:00:00

  • Biological and clinical significance of PARP1 protein expression in breast cancer.

    abstract::Poly(ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair. PARP inhibitors have gained recent attention as promising therapeutic agents for the treatment of solid tumours including breast cancer (BC). However, the biological and clinical significance of PARP1 expression in BC and its role in DNA-damage ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3230-1

    authors: Green AR,Caracappa D,Benhasouna AA,Alshareeda A,Nolan CC,Macmillan RD,Madhusudan S,Ellis IO,Rakha EA

    更新日期:2015-01-01 00:00:00

  • Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial.

    abstract::The aim of this study was to evaluate the effectiveness of an additional, individualized, multi-component complementary medicine treatment offered to breast cancer patients at the Merano Hospital (South Tyrol) on health-related quality of life compared to patients receiving usual care only. A randomized pragmatic tria...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10549-014-3249-3

    authors: Witt CM,Außerer O,Baier S,Heidegger H,Icke K,Mayr O,Mitterer M,Roll S,Spizzo G,Scherer A,Thuile C,Wieser A,Schützler L

    更新日期:2015-01-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract::Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005951125574

    authors: Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期:1998-03-01 00:00:00

  • Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

    abstract::The research question of this investigation is whether the reduction rate of Ki-67 after neoadjuvant chemotherapy (NAC) could indicate a survival in patients with non-pCR. A total of 455 patients had received NAC, and subsequent surgery was analyzed retrospectively. Patients with non-pCR were divided into three subgro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3084-6

    authors: Matsubara N,Mukai H,Masumoto M,Sasaki M,Naito Y,Fujii S,Wada N

    更新日期:2014-08-01 00:00:00